By Justin Yamashita, MSc. Benchtop, site, CRO: three levels of basic and clinical research, explained without spin.

Monday we issued the first Black Box Warning. The flashlight hit the first monster under the bed: Naturella. Her tactic was The Costume, dress a drug in a leaf and let you assume the rest. Wednesday we put both bottles on a lab bench and measured what was inside. Friday, the claims go on trial. Here is the verdict.

Two claims went through the Skeptic’s Toolkit. Two labels came back.

Claim 1: "Berberine is nature’s Ozempic."   Verdict: OVERSOLD

There is a real thing here. Berberine does nudge a few markers, triglycerides, fasting glucose, waist size. But it works through a different pathway than a GLP-1 drug, closer to metformin, and the effect is small.

The one line to remember: berberine is real, but "nature’s Ozempic" is a name, not a result. You are buying the word Ozempic. The bottle cannot cash it.

Claim 2: "Red yeast rice is the natural, drug-free way to lower cholesterol."   Verdict: MISBRANDED

This one is not drug-free. Its active compound, monacolin K, is lovastatin, the identical molecule to a prescription statin. When 28 brands were tested, the dose swung more than 60-fold from one bottle to the next, and no label told you how much you were getting. A prescription statin comes with a measured dose and someone watching your liver. This comes with a leaf on the label and neither.

The one line to remember: "drug-free" red yeast rice is a statin wearing a leaf. Same molecule, unmeasured dose, nobody watching.

Seen in the wild: the natural glowup

This is the part you do not get anywhere else. Every Friday we pin real examples of the week’s tactic next to its verdict, so you can recognize it the next time it slides through your own feed. Here is The Costume, live.

Her handle is blurred, because this isn’t about shaming anyone. This is what Naturella looks like. Naturella isn’t the bad guy. The Broker is, metaphorically.

How we judged it (members’ bench notes)

You don’t just get the ruling, you get the workings. This is the same lens I use in clinical research, from the benchtop to the trial site to the CRO: identity, dose, cause, and who was watching. Berberine and red yeast rice fail the exact checks a study drug has to pass before anyone can sell it. Here’s the bench each claim was scored on.

Identity, is it the same molecule as the drug? Berberine, no. Red yeast rice, yes, monacolin K is lovastatin.

Dose control, is the amount measured and consistent? Berberine, not standardized. Red yeast rice, swings more than 60-fold between brands, with the amount left off the label.

Evidence, how many humans, for how long? Berberine, a small and short randomized-trial base showing modest effects. The GLP-1 drug it borrows from, large and long. Not the same shelf.

Oversight, who is watching after you swallow it? Prescription, a clinician and a monitoring system. Supplement, nobody.

Naming, does the name promise more than the data delivers? Berberine, yes, "nature’s Ozempic" oversells a small effect. Red yeast rice, yes, "drug-free" is simply untrue. Add it up and you get OVERSOLD and MISBRANDED.

What’s actually in it, and who checked the dose? Ask it of berberine and the borrowed name falls off. Ask it of red yeast rice and the statin steps out from behind the leaf. One question, both costumes. That is the one Sam asked you to find at the bench.

The takeaway

Here’s the whole issue in one breath: a costume doesn’t change what’s under it. Berberine borrows a name. Red yeast rice borrows a leaf. Undress either one and you find the same thing, a drug-strength effect with the measuring, the dosing, and the watching stripped out. You do not have to swear off supplements. You have to undress the claim, and be careful with the word safe, because safe means known and watched, not risk-free.

Naturella loses this week. But she was only ever the mannequin. The Broker who dressed her, the market that sells a drug without ever calling it one, is still offscreen. He gets a name soon. Monday, the box opens again, new tactic, same warning. And next issue we follow the costume to its riskiest form: peptides sold as research chemicals, at a moment when the FDA is deciding what to do about them.

Black Box Warning. The strongest alert we can issue.

Want Thursday and Friday too?

The Informed (Thursday) and The Verdict (Friday) do not come automatically. You have to turn them on yourself. It takes ten seconds and it is the only way the full week lands in your inbox.

Opt-in Instructions

Know someone about to fall for this? Hand them the antidote. Refer and collect the Series 1 cards.

References

[1] Liu D, Zhao H, Zhang Y, Hu J, Xu H. Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials. Frontiers in Pharmacology. 2025;16:1572197.

[2] Cohen PA, Avula B, Khan IA. Variability in strength of red yeast rice supplements purchased from mainstream retailers. European Journal of Preventive Cardiology. 2017;24(13):1431 to 1434.

[3] National Center for Complementary and Integrative Health (NIH). Red Yeast Rice. nccih.nih.gov/health/red-yeast-rice

[4] U.S. FDA determination that red yeast rice products containing more than trace monacolin K are unapproved new drugs (Pharmanex v. Shalala, upheld 2001).

Try it yourself: run next week's headline through the same test before the newsletter does. The Skeptic Type quiz sorts you into your pattern in about two minutes: openlabelmedia.com/skeptic-type. Got Skepticism? runs any claim through the same one-question move used above. Stay in the Room shows you how to disagree without a fight. Both play in your browser at openlabelmedia.com, and I would love to see your results on social.

For educational purposes only. Nothing in this newsletter is medical advice. Talk to your doctor before making any health decision.

Instagram: instagram.com/roottorx | Facebook Lab: facebook.com/groups/theroottorxlab | Subscribe: RootToRx.com

Disclosure: Root to Rx is published independently by Open Label Media LLC. Views expressed are personal views of Justin Yamashita and do not represent his employer or any affiliated organization. No employer resources or proprietary information are used. Every claim is sourced from publicly available materials.

Root to Rx | 228 Park Ave S, #29976, New York, New York 10003, United States